A. Malik, Prajjalendra Barooah, Snigdha Saikia, Subhash Medhi, S. Kalita, Manas Jyoti Kalita, P. Das, K. Dutta, Pooja Bharali, M. Sarma, Preeti Sarma, M. Bhattacharyya, P. Kar, B. Goswami, Musaed Alkholief, A. Alshamsan
{"title":"循环MicroRNA-122作为丙型肝炎病毒诱导的肝细胞癌的潜在生物标志物","authors":"A. Malik, Prajjalendra Barooah, Snigdha Saikia, Subhash Medhi, S. Kalita, Manas Jyoti Kalita, P. Das, K. Dutta, Pooja Bharali, M. Sarma, Preeti Sarma, M. Bhattacharyya, P. Kar, B. Goswami, Musaed Alkholief, A. Alshamsan","doi":"10.5812/ijcm-131221","DOIUrl":null,"url":null,"abstract":"Background: The microRNA (miRNA) mediated translational repression can cause various diseases in humans. The liver-specific miRNA (microRNA-122 (miR-122)) is primarily involved in tissue tropism during hepatitis C virus (HCV) infection which ultimately leads to hepatocellular carcinoma (HCC). Objectives: This study focuses on evaluating host serum miR-122 as a prognostic marker in HCV-induced hepatocellular carcinoma. Methods: Evaluation of miR-122 expression was carried out by quantitative real time PCR. Results: Positive expression of miR-122 was observed in patients with chronic hepatitis C (CHC) followed by HCC patients compared to healthy controls. A difference in median levels of the miR-122 expression in CHC and HCC patients (P < 0.000) was found in contrast to cirrhosis patients (P = 0.511). The serum miR-122 expression was found threefold higher in liver cirrhosis patients than chronic hepatitis. Further, the area under the receiver operating characteristic curve (AUROC) analysis of miR-122 expression profile can efficiently distinguish CHC patients (AUROC = 0.978, P = 0.000, 95% confidence interval (CI) = 0.958 to 0.998) and HCC from healthy controls (AUROC = 0.971, P = 0.000, 95% CI = 0.944 to 0.997). Moreover, receiver operating characteristic (ROC) curve analysis significantly distinguished between CHC patients from cirrhosis patients (AUROC = 0.955, P = 0.000, 95% CI = 0.925 to 0.986) but not CHC from HCC patients (AUROC = 0.584, P = 0.104, 95% CI = 0.485 to 0.684). This study revealed a substantial correlation of miR-122 with HCV viral load (r = 0.56, P = 0.000), ALT (r = 0.67, P = 0.000) and AST (r = 0.65, P = 0.000) levels. Conclusions: Serum miR-122 can potentially serve as a promising prognostic tool for HCV induced HCC.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"19 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Circulating MicroRNA-122 as a Potential Biomarker for Hepatitis C Virus Induced Hepatocellular Carcinoma\",\"authors\":\"A. Malik, Prajjalendra Barooah, Snigdha Saikia, Subhash Medhi, S. Kalita, Manas Jyoti Kalita, P. Das, K. Dutta, Pooja Bharali, M. Sarma, Preeti Sarma, M. Bhattacharyya, P. Kar, B. Goswami, Musaed Alkholief, A. Alshamsan\",\"doi\":\"10.5812/ijcm-131221\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The microRNA (miRNA) mediated translational repression can cause various diseases in humans. The liver-specific miRNA (microRNA-122 (miR-122)) is primarily involved in tissue tropism during hepatitis C virus (HCV) infection which ultimately leads to hepatocellular carcinoma (HCC). Objectives: This study focuses on evaluating host serum miR-122 as a prognostic marker in HCV-induced hepatocellular carcinoma. Methods: Evaluation of miR-122 expression was carried out by quantitative real time PCR. Results: Positive expression of miR-122 was observed in patients with chronic hepatitis C (CHC) followed by HCC patients compared to healthy controls. A difference in median levels of the miR-122 expression in CHC and HCC patients (P < 0.000) was found in contrast to cirrhosis patients (P = 0.511). The serum miR-122 expression was found threefold higher in liver cirrhosis patients than chronic hepatitis. Further, the area under the receiver operating characteristic curve (AUROC) analysis of miR-122 expression profile can efficiently distinguish CHC patients (AUROC = 0.978, P = 0.000, 95% confidence interval (CI) = 0.958 to 0.998) and HCC from healthy controls (AUROC = 0.971, P = 0.000, 95% CI = 0.944 to 0.997). Moreover, receiver operating characteristic (ROC) curve analysis significantly distinguished between CHC patients from cirrhosis patients (AUROC = 0.955, P = 0.000, 95% CI = 0.925 to 0.986) but not CHC from HCC patients (AUROC = 0.584, P = 0.104, 95% CI = 0.485 to 0.684). This study revealed a substantial correlation of miR-122 with HCV viral load (r = 0.56, P = 0.000), ALT (r = 0.67, P = 0.000) and AST (r = 0.65, P = 0.000) levels. Conclusions: Serum miR-122 can potentially serve as a promising prognostic tool for HCV induced HCC.\",\"PeriodicalId\":44764,\"journal\":{\"name\":\"International Journal of Cancer Management\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-11-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5812/ijcm-131221\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-131221","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1
摘要
背景:miRNA介导的翻译抑制可引起人类多种疾病。肝脏特异性miRNA (microRNA-122 (miR-122))主要参与丙型肝炎病毒(HCV)感染期间的组织趋向性,最终导致肝细胞癌(HCC)。目的:本研究的重点是评估宿主血清miR-122作为hcv诱导的肝细胞癌的预后标志物。方法:采用实时荧光定量PCR法检测miR-122的表达。结果:与健康对照组相比,miR-122在慢性丙型肝炎(CHC)患者和HCC患者中呈阳性表达。与肝硬化患者相比,CHC和HCC患者miR-122的中位表达水平存在差异(P < 0.000) (P = 0.511)。肝硬化患者血清miR-122表达比慢性肝炎患者高3倍。此外,miR-122表达谱的受试者工作特征曲线下面积(AUROC)分析可以有效区分CHC患者(AUROC = 0.978, P = 0.000, 95%可信区间(CI) = 0.958 ~ 0.998)和健康对照组的HCC (AUROC = 0.971, P = 0.000, 95% CI = 0.944 ~ 0.997)。此外,受试者工作特征(ROC)曲线分析在CHC患者与肝硬化患者之间有显著差异(AUROC = 0.955, P = 0.000, 95% CI = 0.925 ~ 0.986),而HCC患者之间无显著差异(AUROC = 0.584, P = 0.104, 95% CI = 0.485 ~ 0.684)。本研究显示miR-122与HCV病毒载量(r = 0.56, P = 0.000)、ALT (r = 0.67, P = 0.000)和AST (r = 0.65, P = 0.000)水平存在显著相关性。结论:血清miR-122可能作为HCV诱导的HCC的预后工具。
Circulating MicroRNA-122 as a Potential Biomarker for Hepatitis C Virus Induced Hepatocellular Carcinoma
Background: The microRNA (miRNA) mediated translational repression can cause various diseases in humans. The liver-specific miRNA (microRNA-122 (miR-122)) is primarily involved in tissue tropism during hepatitis C virus (HCV) infection which ultimately leads to hepatocellular carcinoma (HCC). Objectives: This study focuses on evaluating host serum miR-122 as a prognostic marker in HCV-induced hepatocellular carcinoma. Methods: Evaluation of miR-122 expression was carried out by quantitative real time PCR. Results: Positive expression of miR-122 was observed in patients with chronic hepatitis C (CHC) followed by HCC patients compared to healthy controls. A difference in median levels of the miR-122 expression in CHC and HCC patients (P < 0.000) was found in contrast to cirrhosis patients (P = 0.511). The serum miR-122 expression was found threefold higher in liver cirrhosis patients than chronic hepatitis. Further, the area under the receiver operating characteristic curve (AUROC) analysis of miR-122 expression profile can efficiently distinguish CHC patients (AUROC = 0.978, P = 0.000, 95% confidence interval (CI) = 0.958 to 0.998) and HCC from healthy controls (AUROC = 0.971, P = 0.000, 95% CI = 0.944 to 0.997). Moreover, receiver operating characteristic (ROC) curve analysis significantly distinguished between CHC patients from cirrhosis patients (AUROC = 0.955, P = 0.000, 95% CI = 0.925 to 0.986) but not CHC from HCC patients (AUROC = 0.584, P = 0.104, 95% CI = 0.485 to 0.684). This study revealed a substantial correlation of miR-122 with HCV viral load (r = 0.56, P = 0.000), ALT (r = 0.67, P = 0.000) and AST (r = 0.65, P = 0.000) levels. Conclusions: Serum miR-122 can potentially serve as a promising prognostic tool for HCV induced HCC.
期刊介绍:
International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.